Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?

摘要: Colony stimulating factors (CSF) have been shown to reduce the duration of neutropenia following intensive chemotherapy in a variety settings, with many these studies targeting older patients leukaemia. We review clinical and economic findings for use growth adults acute myelogenous leukaemia (AML). The cost analyses were based on perspective third party payer. One study, conducted by Southwest Oncology Group (SWOG) randomised 207 AML receive granulocyte colony-stimulating factor (G-CSF) or placebo found no significant difference number infections days hospitalisation, 3 fewer an absolute neutrophil count <500 cells/μL G-CSF, estimated incremental only $US120 G-CSF over (1997 costs). A second Eastern Cooperative (ECOG), 119 granulocyte-macrophage (GM-CSF) reduction severe infections, 4 cells/μL, savings $US2310 GM-CSF These data may be useful physicians faced concerns associated CSF as adjunct therapy persons AML.